Fractalkine, a CX3C Chemokine, Act as a Mediator of Ocular Angiogenesis

This study has been completed.
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT00728598
First received: August 1, 2008
Last updated: August 5, 2008
Last verified: August 2008
  Purpose

Fractalkine (FKN) is a chemoattractant and adhesion molecule for leukocytes. Angiogenic effect of FKN also has been reported. We investigate FKN-mediated angiogenesis in ocular angiogenic disorders.


Condition
Proliferative Diabetic Retinopathy
Angiogenesis

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Vitreous Levels of Patients With Proliferative Diabetic Retinopathy.

Resource links provided by NLM:


Further study details as provided by National Taiwan University Hospital:

Primary Outcome Measures:
  • Vitreous levels and serum levels of Fractalkine, VEGF, other growth factor. [ Time Frame: vitreous sample collected on vitrectomy ] [ Designated as safety issue: Yes ]

Biospecimen Retention:   Samples Without DNA

Vitreous sample and blood sample


Enrollment: 30
Study Start Date: January 1998
Study Completion Date: December 1998
Primary Completion Date: December 1998 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Proliferative diabetic retinopathy, active.
2
Proliferative diabetic retinopathy, quiescent.
3
Control group. Patients with macular hole or idiopathic epiretinal membrane receiving vitrectomy for their disease.

Detailed Description:

Fractalkine (FKN), the sole member of the CX3C chemokine family, is named for its fractal geometry. The CX3C motif, with three amino acids between the two terminal cysteines, makes fractalkine distinct from other chemokines.The structure of fractalkine, a membrane-bound glycoprotein with the chemokines domain atop an extended mucin-like stalk, also is unique.Membrane-bound FKN can be markedly induced on primary endothelial cells by inflammatory cytokines; this form promotes the robust adhesion of monocytes and T lymphocytes. Soluble FKN can be released by proteolysis at an efficient chemotactic activity level for monocytes and T cells. Thus, FKN is a versatile molecule regulating both cell-cell interactions in its membrane-bound form and directed-cell migration in its soluble form. The receptor of FKN, CXC3R1, is a G protein-couple protein, which expresses T lymphocytes, monocytes, natural killer (NK) cells, microglia, and neurons.Sulfation of tyrosine enhances the function of CX3CR1 in cell capture and firm adhesion. Fractalkine is expressed constitutively in the kidney, heart, lung, and brain. Fractalkine has demonstrated an important role in CNS inflammation, cardiac allograft rejection, arteriogenesis, renal disease, psoriasis, and during pregnancy. Silverman et al demonstrated the presence of FKN in normal cultured microvascular endothelial and stromal cells of iris and retina in vitro. Upon inflammatory cytokine stimulation, EC also express FKN and its receptors with FKN secretion in an autocrine manner. In addition to EC chemotaxis and tube formation, FKN is an angiogenic mediator in rheumatoid arthritis. Therefore, we hypothesize that FKN not only participates in ocular inflammatory reactions, but also plays an important role in ocular angiogenesis.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with proliferative diabetic retinopathy, who will receive vitrectomy.

Criteria

Inclusion Criteria:

  • clinical diagnosis of proliferative diabetic retinopathy.
  • who will receive vitrectomy for treatment of disease.

Exclusion Criteria:

  • previous ocular surgical history.
  • history of uveitis
  • history of ocular trauma.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00728598

Locations
Taiwan
The department of ophthalmology, National Taiwan University Hospital
Taipei, Taiwan
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Principal Investigator: Chang-Hao Yang, MD, PhD Ophthalmology, National Taiwan University Hospital
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00728598     History of Changes
Other Study ID Numbers: 9561702008
Study First Received: August 1, 2008
Last Updated: August 5, 2008
Health Authority: Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:
Proliferative diabetic retinopathy
Angiogenesis
Vitreous levels
Vascular endothelial growth factor
Fractalkine
Growth factor

Additional relevant MeSH terms:
Diabetic Retinopathy
Retinal Diseases
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases

ClinicalTrials.gov processed this record on April 17, 2014